抗结核药物的群体药代动力学与贝叶斯剂量调整推进TDM
该综述更新了抗结核药物的药代动力学与药效学,并展示群体药代动力学与贝叶斯剂量调整如何优化治疗。研究覆盖药物敏感及耐多药结核所用药物,汇总了支持治疗药物监测的数据及可用的药代动力学/药效学靶标。作者建议加强研究者与WHO合作以更新TDM及PK/PD指南。
要点
- 群体PK模型已覆盖一线和二线抗结核药物,可支持贝叶斯剂量调整。
- 需研究者与WHO协作更新TDM及PK/PD相关指南。
核心结论
- 群体药代动力学与贝叶斯剂量调整可用于优化抗结核治疗,并有助于预防应答缓慢、获得性耐药和药物不良反应。
研究设计与样本
- 本文为综述,覆盖药物敏感结核和耐多药结核所用药物的临床前、临床及群体药代动力学。
主要发现
- 已识别出大量用于结核一线和二线药物的群体药代动力学模型,模型基于NONMEM、Pmetrics、ADAPT、MWPharm、Monolix、Phoenix和NPEM2软件构建。
- 最早的群体模型针对异烟肼和利福平构建;近年来新型抗结核药物及老药靶标定义的数据有所增加。
关键数值与推荐
- 建议研究者与WHO密切合作,提供关于TDM及PK/PD的重要指南更新。
临床怎么用
- 临床可依据群体PK模型和贝叶斯剂量调整开展抗结核药物TDM,以优化治疗并减少应答缓慢、获得性耐药和不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tuberculosis (TB) is still the number one cause of death due to an infectious disease. Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB treatment and help to prevent slow response to treatment, acquired drug resistance, and adverse drug effects. The aim of this review was to provide an update on the pharmacokinetics and pharmacodynamics of anti-TB drugs and to show how population pharmacokinetics and Bayesian dose adjustment can be used to optimize treatment. We cover aspects on preclinical, clinical, and population pharmacokinetics of different drugs used for drug-susceptible TB and multidrug-resistant TB. Moreover, we include available data to support therapeutic drug monitoring of these drugs and known pharmacokinetic and pharmacodynamic targets that can be used for optimization of therapy. We have identified a wide range of population pharmacokinetic models for first- and second-line drugs used for TB, which included models built on NONMEM, Pmetrics, ADAPT, MWPharm, Monolix, Phoenix, and NPEM2 software. The first population models were built for isoniazid and rifampicin; however, in recent years, more data have emerged for both new anti-TB drugs, but also for defining targets of older anti-TB drugs. Since the introduction of therapeutic drug monitoring for TB over 3 decades ago, further development of therapeutic drug monitoring in TB next steps will again depend on academic and clinical initiatives. We recommend close collaboration between researchers and the World Health Organization to provide important guideline updates regarding therapeutic drug monitoring and pharmacokinetics/pharmacodynamics.
引用
- Sturkenboom MGG, Märtson AG, Svensson EM, et al. Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clin Pharmacokinet. 2021. PMID: 33674941. doi:10.1007/s40262-021-00997-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。